Clinical Trial Update: Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of Calcipotriene 0.005% Foam under maximal use in 12-16-year-olds with plaq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Calcipotriene 0.005% Foam (calcipotriene)

Snippet

Sponsor: Mayne Pharma International Pty Ltd | Conditions: Psoriasis | Phase 1 | Status: COMPLETED